Working…
Help guide our efforts to modernize ClinicalTrials.gov.
Send us your comments by March 14, 2020.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Nivolumab in Patients With High-Risk Biochemically Recurrent Prostate Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03637543
Recruitment Status : Recruiting
First Posted : August 20, 2018
Last Update Posted : August 28, 2019
Sponsor:
Collaborator:
Bristol-Myers Squibb
Information provided by (Responsible Party):
David J. Einstein, MD, Beth Israel Deaconess Medical Center

Brief Summary:

This research study is studying an immune-based cancer drug as a possible treatment for prostate cancer.

The drug involved in this study is:

-Nivolumab


Condition or disease Intervention/treatment Phase
Prostate Cancer Drug: Nivolumab Phase 2

Detailed Description:

This research study is a Phase II clinical trial. Phase II clinical trials test the safety and effectiveness of an investigational drug to learn whether the drug works in treating a specific disease. "Investigational" means that the drug is being studied.

The FDA (the U.S. Food and Drug Administration) has not approved nivolumab for this specific disease but it has been approved for other uses. Nivolumab is an antibody inhibitor of the programmed death-1 (PD-1) pathway. By blocking PD-1, this medication may allow the immune system to recognize and fight cancer.

In this research study, the investigators are investigating whether nivolumab has any activity in patients who have a rising PSA (prostate specific antigen) after previously undergoing surgery or radiation for prostate cancer. Although nivolumab was previously not found to have significant effect in advanced prostate cancer after all other therapies had failed, based on new research, the investigators are testing whether nivolumab could have a greater effect earlier in the disease course and before patients receive hormone therapies.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 34 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 2 Study of Nivolumab in Patients With High-Risk Biochemically Recurrent Prostate Cancer
Actual Study Start Date : October 18, 2018
Estimated Primary Completion Date : March 31, 2022
Estimated Study Completion Date : March 31, 2025

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Prostate Cancer
Drug Information available for: Nivolumab

Arm Intervention/treatment
Experimental: PD-L1 Positive
-Nivolumab will be given on day 1 of a 28-day cycle intravenously
Drug: Nivolumab
Nivolumab is an antibody inhibitor of the programmed death-1 (PD-1) pathway. By blocking PD-1, this medication may allow the immune system to recognize and fight cancer
Other Name: Opdivo

Experimental: PD-L1 Negative
-Nivolumab will be given on day 1 of a 28-day cycle intravenously
Drug: Nivolumab
Nivolumab is an antibody inhibitor of the programmed death-1 (PD-1) pathway. By blocking PD-1, this medication may allow the immune system to recognize and fight cancer
Other Name: Opdivo




Primary Outcome Measures :
  1. Disease Control [ Time Frame: 12 weeks ]
    Proportion of patients with high-risk biochemically-recurrent (BCR) prostate cancer (PCa) that experiences decline or stabilization in PSA (without symptomatic/radiographic progression) after 12 weeks of nivolumab treatment


Secondary Outcome Measures :
  1. Maximal change in prostate specific antigen (PSA) during nivolumab treatment [ Time Frame: 2 years ]
  2. Best PSA response during nivolumab treatment as an absolute change relative to baseline [ Time Frame: 2 years ]
  3. Change in PSA doubling time (PSADT) at end-of-study relative to baseline [ Time Frame: 2 years ]
  4. Time from enrollment to development of radiographic metastatic disease [ Time Frame: 2 years ]
  5. Time from enrollment to initiation of androgen deprivation therapy (ADT) [ Time Frame: 2 years ]
  6. Treatment-related adverse events as assessed by CTCAE v5.0 [ Time Frame: 2 years ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients must have signed an informed-consent form indicating that the patient understands the purpose of and procedures required for the study and is willing to participate in the study.
  • Patients must have a history of prostate adenocarcinoma (adenocarcinoma must be the primary histology; secondary components of variant histologies are acceptable) confirmed on biopsy and treated with primary radical prostatectomy (RP) or definitive radiation (RT). Prior salvage RT is acceptable.
  • Patients must have experienced biochemical recurrence (BCR) defined as:

    • Following primary RP: Any detectable rising PSA after RP (or after salvage RT if performed)
    • Following primary RT: PSA rise to ≥2 ng/mL above the nadir
    • No evidence of metastases on conventional imaging (CT or MRI plus bone scan)
  • PSA doubling time (PSADT) <10 months --PSADT: calculated as per Prostate Cancer Working Group 3 (PCWG3) and the Memorial Sloan Kettering Cancer Center calculator: (https://www.mskcc.org/nomograms/prostate/psa_doubling_time)

With linear regression model of normal logarithm of PSA and time, based on:

  • At least 3 consecutive PSA values with each value ≥0.2 ng/mL
  • Interval between first and last PSA values is ≥8 weeks but ≤12 months

    • Most recent PSA ≥2.0 ng/mL
    • Archival tissue is mandatory, either prostatectomy specimen or (in patients who received primary RT) diagnostic core biopsies. Patients must consent to next-generation sequencing performed on this tissue.
  • If diagnostic core biopsies are only available tissue, at least 3 cores must be involved by tumor

    • Easteron Cooperative Oncology Group (ECOG) performance status 0-1
    • Age ≥18 years
    • Adequate organ and marrow function:
    • System Laboratory Value
  • Hematological
  • White blood cell (WBC) ≥ 2000/µL
  • Absolute Neutrophil Count (ANC) ≥ 1500/μL
  • Platelets (Plt) ≥ 100 x103/μL
  • Hemoglobin (Hgb) > 9.0 g/dL (with or without transfusion)

    -Renal

  • Serum Creatinine ≤ 2 x ULN
  • Hepatic
  • Bilirubin1 ≤ 1.5× upper limit of normal (ULN)
  • Aspartate aminotransferase (AST) ≤ 3 × ULN
  • Alanine aminotransferase (ALT) ≤ 3 × ULN

    • Except subjects with Gilbert Syndrome, who can have total bilirubin < 3.0 mg/dL
    • Baseline testosterone ≥100 ng/dL
    • Recovery from acute toxicity related to prior therapy, including surgery and radiation, or no treatment-related toxicity ≥ grade 2.
    • History of prior malignancy or concurrent separate malignancy is not an exclusion criterion so long as the non-prostate malignancy is stable and does not require any treatment.
    • Able to understand and sign informed consent and adhere to study procedures.
    • Male patients whose female partners are of reproductive potential must agree to use a contraception during the trial period

Exclusion Criteria:

  • Current use of ADT or plan to initiate ADT during trial period
  • Major surgery or radiation therapy within 14 days of starting study treatment
  • Subjects with active autoimmune disease. Patients with a history of autoimmune disease that has not required systemic immunosuppressive therapy or does not threaten vital organ function including central nervous system, heart, lungs, kidneys, skin, and gastrointestinal tract will be allowed.
  • Known history of immune deficiencies or chronic viral infections including HIV, hepatitis B (HBV), and hepatitis C (HCV) (patients with prior therapy for HBV or HCV is permitted if viral clearance was documented).
  • Concurrent medical condition requiring use of systemic corticosteroids with prednisone >10 mg per day or equivalent. Use of inhaled, nasal, and topical steroids (applied to small body areas) is allowed.
  • Current use (within past 4 weeks) of other prohibited medications including anti-cancer therapies, hormonal therapies, 5-alpha reductase inhibitors, and alternative medications known to alter PSA (e.g. phytoestrogens and saw palmetto).
  • Prior treatment with immune checkpoint inhibitors. (Prior cancer vaccines are allowed.)
  • Serious intercurrent medical or psychiatric illness that, in the judgment of the investigator, would interfere with patient's ability to carry out the treatment program

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03637543


Contacts
Layout table for location contacts
Contact: David J. Einstein, MD 617-667-2100 deinstei@bidmc.harvard.edu

Locations
Layout table for location information
United States, Massachusetts
Beth Israel Deaconess Medical Center Recruiting
Boston, Massachusetts, United States, 02215
Contact: David J. Einstein, MD    617-667-2100    deinstei@bidmc.harvard.edu   
Principal Investigator: David J. Einstein, MD         
Dana Farber Cancer Institute Recruiting
Boston, Massachusetts, United States, 02215
Contact: Xiao Wei, MD       XiaoX_Wei@DFCI.HARVARD.EDU   
Principal Investigator: Xiao Wei, MD         
Sponsors and Collaborators
Beth Israel Deaconess Medical Center
Bristol-Myers Squibb
Investigators
Layout table for investigator information
Principal Investigator: David J. Einstein, MD Beth Israel Deaconess Medical Center

Layout table for additonal information
Responsible Party: David J. Einstein, MD, Principal Investigator, Beth Israel Deaconess Medical Center
ClinicalTrials.gov Identifier: NCT03637543    
Other Study ID Numbers: 18-249
First Posted: August 20, 2018    Key Record Dates
Last Update Posted: August 28, 2019
Last Verified: August 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by David J. Einstein, MD, Beth Israel Deaconess Medical Center:
Prostate Cancer
Additional relevant MeSH terms:
Layout table for MeSH terms
Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Neoplasms
Genital Diseases, Male
Prostatic Diseases
Nivolumab
Antineoplastic Agents, Immunological
Antineoplastic Agents